Combination therapy trial of panitumumab(Pmab) with FOLFIRI for inoperable advanced recurrent colorectal cancer first-line chemotherapy

Phase 4

• Conditions: advanced and recurrent colorectal cancer

• Registration Number: JPRN-UMIN000005196
• Lead Sponsor: Kyoto Prefectural University of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-03-16
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Not provided

Exclusion Criteria

1)A history of CPT-11 use 2)Contraindications to panitumumab 3)Contraindications to irinotecan 1.Severe bone marrow suppression 2.infection 3.Diarrhea 4.intestinal paralysis and intestinal obstruction 5.interstitial pneumonia, pulmonary fibrosis 6.Massive pleural or abdominal effusion 7. Icterus 8.Need to treatment with atazanavir sulfate 9.History of serious drug hypersensitivity " 4)Any other cases who are regarded as inadequate for study enrollment by the investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall response rate

Secondary Outcome Measures

Name	Time	Method
Progression-free survival Overall Survival Safety Efficacy according to B-RAF status (ORR,PFS,OS,Safety)